Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking, as regards the definition of drug
Date: 2013-09-17
Institutions: European Commission
Subjects: drug traffic, penalty, psychotropic substance, public health













EUR-Lex - 52013PC0618 - EN











|



52013PC0618

Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking, as regards the definition of drug /* COM/2013/0618 final - 2013/0304 (COD) */









 EN 
 || EUROPEAN COMMISSION ||   
Brussels, 17.9.2013 
COM(2013) 618 final
2013/0304
(COD)
 
Proposal for a
DIRECTIVE OF THE
EUROPEAN PARLIAMENT AND OF THE COUNCIL
amending Council Framework
Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the
constituent elements of criminal acts and penalties in the field of illicit
drug trafficking, as regards the definition of drug
{SWD(2013) 319 final}
{SWD(2013) 320 final}
EXPLANATORY MEMORANDUM
1.           CONTEXT OF THE PROPOSAL
1.1.      General context
Illicit drug trafficking and drug abuse are
major threats to the health and safety of individuals and to societies in the
EU. They affect the social and economic fabric and undermine the quality of
life of individuals, as well as the security of the Member States. Although
consumption of substances controlled under the UN Conventions on drugs[1], such as cocaine, ecstasy or
cannabis (‘controlled drugs’), seems to have stabilised in recent years[2], albeit at high levels, a major
challenge is to address new substances that emerge on the market at a rapid
speed. 
New psychoactive substances, which imitate
the effects of controlled drugs and are often marketed as legal alternatives to
them because they are not subjected to similar control measures, and which have
numerous uses in the industry, are increasingly available in the Union. Between 1997 and 2012, Member States reported around 290 substances, with more than
one new substance notified every week in 2012. The number of reported substances
tripled between 2009 and 2012 (from 24 to 73). 
A growing number of individuals, in particular
young people, consume new psychoactive substances. However, these substances
can cause harms to individuals’ health and safety, and can put burdens on
society, just like controlled drugs do. The risks that new psychoactive
substances can pose have prompted national authorities to submit them to
various restriction measures. However, such national restriction measures have
limited effectiveness, since these substances can be moved freely in the
internal market - around 80% of the substances notified were detected in more
than one Member State. 
The Commission Communication "Towards
a stronger European response to drugs"[3],
adopted in October 2011, identified new psychoactive substances as one of the
problems requiring a firm response at the EU level.
Council Decision 2005/387/JHA of 10 May
2005[4] provides a mechanism for
addressing the risks posed by new psychoactive substances, which can lead to
the submission of substances to control measures and criminal penalties across
the Union. To address more sustainably the frequent emergence of new
psychoactive substances and their rapid spread across the Union, the Commission
proposed stronger rules, under [Regulation (EU) No …/… on new psychoactive substances].
To effectively reduce the availability of
harmful new psychoactive substances, which pose severe health, social and
safety risks to individuals and society, and to deter trafficking in these
substances as well as the involvement of criminal organisations in their
production or distribution, along with controlled drugs, it is necessary to
cover new psychoactive substances by criminal law provisions.
Council Framework Decision 2004/757/JHA of
25 October 2004[5]
provides a common approach to the fight against illicit drug trafficking. It
sets out minimum common rules on the definition of drug trafficking offences
and sanctions to avoid that problems arise in cooperation between the judicial
authorities and law enforcement agencies of Member States, owing to the fact
that the offence or offences in question are not punishable under the laws of
both the requesting and the requested State. However, while these provisions
apply to substances covered by the UN Conventions and to synthetic drugs
submitted to control under Joint Action 97/396/JHA of 16 June 1997[6], they do not apply to new
psychoactive substances. 
In order to streamline and clarify the
legal framework applicable to drugs, the most harmful new psychoactive
substances should be covered by the same criminal law provisions as substances
controlled under the UN Conventions. 
It is, therefore, necessary to extend the
scope of application of Framework Decision 2004/757/JHA to new psychoactive
substances subjected to control measures under Council Decision 2005/387/JHA as
well as to those substances subjected to permanent market restriction measures
under [Regulation (EU) No …/… on new psychoactive substances]. 
A legislative proposal on illicit drug
trafficking was foreseen in the Commission’s 2012 Work Programme.
1.2.      Grounds for and objectives of
the proposal
This proposal amends Framework Decision
2004/757/JHA to include new psychoactive substances posing severe risks within
its scope of application. 
This proposal accompanies the proposal for
a [Regulation (EU) No …/… on new psychoactive substances]. The two
proposals are linked, so that new psychoactive substances that pose severe
health, social and safety risks and are therefore submitted to permanent market
restriction under that Regulation are also subjected to the criminal law
provisions on illicit drug trafficking set by the Framework Decision
2004/757/JHA.
2.           RESULTS OF CONSULTATIONS
WITH THE INTERESTED PARTIES AND IMPACT ASSESSMENT
2.1.        Stakeholders' consultation
Broad stakeholder and expert consultations and
a web-based public consultation have informed the preparatory work for this
proposal. 
The Commission consulted all Member States
in the assessment of the functioning of Framework Decision 2004/757/JHA and Council
Decision 2005/387/JHA. Moreover, in the context of external studies on illicit
drug trafficking and new psychoactive substances, the Commission collected and
examined the views of a broad range of stakeholders, practitioners and experts,
including EU agencies involved in the implementation of these instruments.
The Commission also organised two experts'
meeting on illicit drug trafficking, on 10 November 2011 and 29 February 2012, and
two experts' meetings on new psychoactive substances, on 15 December 2011 and 1
March 2012. During these meetings, academic experts and practitioners stressed
the importance of criminal law provisions in helping clamp down and deter
illicit drug trafficking, and tackling the spread of harmful new psychoactive
substances. At the same time, they pointed out that legislation on new
psychoactive substances should be proportionate and calibrated to the different
levels of risks that they pose. 
A survey was conducted among young people
(15-24 years' old) in 2011, through the Eurobarometer "Youth attitudes on
drugs". Almost half of respondents (47%) thought that only those
substances which are proved to pose risks to health should be restricted, while
34% held that all substances which imitate the effects of controlled drugs
should be restricted.
2.2.        Impact assessment
The Commission assessed the impacts of this
proposal for an amendment to Framework Decision 2004/757/JHA in an impact assessment
on new psychoactive substances. The analysis concluded that, as under the
Council Decision 2005/387/JHA, harmful new psychoactive substances (those
posing severe health, social and safety risks) should be subjected to criminal
law provisions. It further concluded that they should, therefore, be subjected
to the criminal law provisions on illicit drug trafficking. This represented
part of the preferred policy option, which foresees a graduated set of
restriction measures that are proportionate to the level of risks posed by new
psychoactive substances, and which do not cause obstacles to legitimate trade
in the internal market.
3.           LEGAL ELEMENTS OF THE
PROPOSAL
3.1.        The legal base
This proposal is based on Article 83(1)
TFEU, which empowers the European Parliament and the Council to establish
minimum rules concerning the definition of offences and sanctions in the area
of illicit drug trafficking, by means of a Directive adopted in accordance with
the ordinary legislative procedure.
3.2.        Subsidiarity,
proportionality and respect of fundamental rights
The EU is better placed than the Member
States to take action to restrict the availability in the internal market of
harmful new psychoactive substances for consumers, while simultaneously
ensuring that legitimate trade is not impeded. 
This is because individually Member States
cannot address effectively and sustainably the rapid emergence and spread of
these substances. Uncoordinated national action and the proliferation of
diverse national regimes on new psychoactive substances can produce knock-on
effects on other Member States (displacement of harmful substances) and can pose
problems in cooperation between national judicial authorities and law
enforcement agencies.
The proposal is proportionate and does not
go beyond what is necessary to achieve the objectives because it only addresses
through criminal law those new psychoactive substances that are a serious concern
at the EU level.
This proposal
indirectly impacts on certain fundamental rights and principles enshrined in
the EU Charter of Fundamental Rights, because it expands the scope of
application of the Framework Decision 2004/757/JHA, whose provisions impact on
the following fundamental rights and principles: the right to liberty and
security (Article 6), the right to property (Article 17), the right to an
effective remedy and to a fair trial (Article 47), the presumption of innocence
and right to defence (Article 48), and the principle of legality and
proportionality of criminal offences and penalties (Article 49). These rights
and freedoms can be subject to limitations, but only under the limits and
requirements set by Article 52(1) of the EU Charter.
3.3.        Choice of instrument
In accordance
with Article 83(1) TFEU, a Directive is the appropriate instrument to ensure
minimum harmonisation at the EU level in the area of illicit drug trafficking,
while leaving flexibility to Member States when implementing the principles,
rules and their exemptions at national level.
3.4.        Explanatory documents
accompanying notification of transposition measures
Member States are requested to communicate
to the Commission the national measures adopted to comply with this Directive.
Member States are not requested to submit
to the Commission explanatory documents (including correlation tables)
accompanying the notification of national measures adopted for transposing the
provisions of this Directive. This is not necessary because of the reduced
scope of the proposed amendment. The submission of additional explanatory
documents would add an unjustified administrative burden on Member States'
competent authorities.
3.5.        Main provisions
Article 1 – this
provision lays down the amendments to the Framework Decision 2004/757/JHA, in
relation to the definition of the term "drug", to the provision for covering by criminal law new psychoactive substances posing
severe health, social and safety risks, and to the assessment of the implementation and impacts of the Framework
Decision by the Commission.
Article 2 –
this provision lays down the deadline for the transposition of the provisions
of the Directive in national legislation.
Articles 3 and 4 – these provisions relate to the entry into force and addressees of
the Directive.
4.           BUDGETARY IMPLICATION
The proposal has no implications for the
Union budget.
2013/0304 (COD)
Proposal for a
DIRECTIVE OF THE EUROPEAN PARLIAMENT
AND OF THE COUNCIL
amending Council Framework Decision
2004/757/JHA of 25 October 2004 laying down minimum provisions on the
constituent elements of criminal acts and penalties in the field of illicit
drug trafficking, as regards the definition of drug
THE EUROPEAN PARLIAMENT AND THE
COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the
Functioning of the European Union, and in particular Article 83(1) thereof,
Having regard to the proposal from the
European Commission,
After transmission of the draft legislative
act to the national parliaments,
Acting in accordance with the ordinary
legislative procedure,
Whereas:
(1)       Council Framework Decision
2004/757/JHA of 25 October 2004 laying down minimum provisions on the
constituent elements of criminal acts and penalties in the field of illicit
drug trafficking[7]
provides a common approach to the fight against illicit drug trafficking, which
poses a threat to the health, safety and quality of life of citizens of the
Union, and to the legal economy, stability and security of the Member States.
It sets out minimum common rules on the definition of drug trafficking offences
and sanctions, to avoid that problems may arise in cooperation between the
judicial authorities and law enforcement agencies of Member States, owing to
the fact that the offence or offences in question are not punishable under the
laws of both the requesting and the requested State.
(2)       Framework Decision
2004/757/JHA applies to the substances covered by the 1961 United Nations
Single Convention on Narcotic Drugs, as amended by the 1972 Protocol, and the
1971 United Nations Convention on Psychotropic Substances (‘UN Conventions’),
as well as to the synthetic drugs subjected to control across the Union
pursuant to Joint Action 97/396/JHA of 16 June 1997 concerning the information
exchange, risk assessment and the control of new synthetic drugs[8], which pose public health risks
comparable to those posed by the substances scheduled under the UN Conventions.
(3)       Framework Decision
2004/757/JHA should also apply to the substances subjected to control measures
and criminal penalties pursuant to Council Decision 2005/387/JHA of 10 May 2005
on the information exchange, risk assessment and control of new psychoactive
substances[9],
which pose public health risks comparable to those posed by the substances
scheduled under the UN Conventions.
(4)       New psychoactive
substances, which imitate the effects of substances scheduled under the UN
Conventions, are emerging frequently and are spreading fast in the Union. Certain new psychoactive substances pose severe health, social and safety risks, as
ascertained by [Regulation (EU) No …/… on new psychoactive substances].
Under that Regulation, measures may be taken to prohibit the production,
manufacture, making available on the market including importation to the Union,
transport, and exportation from the Union of new psychoactive substances posing
severe health, social and safety risks. To effectively reduce the availability
of new psychoactive substances that pose severe risks to individuals and society,
and to deter trafficking in those substances across the Union, as well as the
involvement of criminal organisations, permanent market restriction measures
adopted under that Regulation should be underpinned by criminal law provisions.
(5)       The new psychoactive
substances subjected to permanent market restriction pursuant to [Regulation
(EU) No …/… on new psychoactive substances] should, therefore, be covered
by the Union criminal law provisions on illicit drug trafficking. This would
also help streamline and clarify the Union legal framework, as the same
criminal law provisions would apply to substances covered by the UN Conventions
and to the most harmful new psychoactive substances. The definition of 'drug'
in the Framework Decision 2004/757/JHA should, therefore, be amended. 
(6)       In order to swiftly
address the emergence and spread of harmful new psychoactive substances in the
Union, Member States should apply the provisions of the Framework Decision
2004/757/JHA to new psychoactive substances posing severe health, social and
safety risks within twelve months from their submission to permanent market
restriction under [Regulation (EU) No …/… on new psychoactive substances].
(7)       Since the objective of this
Directive, namely to extend the application of the Union criminal law
provisions that apply to illicit drug trafficking to new psychoactive
substances posing severe health, social and safety risks, cannot be
sufficiently achieved by the Member States acting alone, and can therefore be
better achieved at the Union level, the Union may adopt measures, in accordance
with the principle of subsidiarity as set out in Article 5 of the Treaty on the
European Union. In accordance with the principle of proportionality, as set out
in that Article, this Directive does not go beyond what is necessary in order
to achieve its objective. 
(8)       This Directive respects
the fundamental rights and observes the principles recognised by the Charter of
Fundamental Rights of the European Union, and notably the right to an effective
remedy and to a fair trial, the presumption of innocence and the right of
defence, the right not to be tried or punished twice in criminal proceedings
for the same criminal offence and the principles of legality and proportionality
of criminal offences.
(9)       [In accordance with
Article 3 of the Protocol (No 21) on the position of the United Kingdom and
Ireland in respect of the area of freedom, security and justice, annexed to the
Treaty on the European Union and to the Treaty on the Functioning of the
European Union, the United Kingdom and Ireland have notified their wish to take
part in the adoption and application of this Directive.]
AND/OR
(10)     [In accordance with
Articles 1 and 2 of the Protocol (No 21) on the position of the United Kingdom
and Ireland in respect of the area of freedom, security and justice, annexed to
the Treaty on the European Union and to the Treaty on the Functioning of the
European Union, and without prejudice to Article 4 of that Protocol, the United
Kingdom and Ireland are not taking part in the adoption of this Directive and are
not bound by or subject to its application.]
(11)     In accordance with Articles
1 and 2 of the Protocol (No 22) on the position of Denmark annexed to the
Treaty on the European Union and to the Treaty on the Functioning of the
European Union, Denmark is not taking part in the adoption of this Directive
and is therefore not bound by or subject to its application.
(12)     Framework
Decision 2004/757/JHA should therefore be amended accordingly,
HAVE ADOPTED THIS DIRECTIVE:
Article 1
Framework Decision 2004/757/JHA is amended
as follows:
(1)                   
In Article 1, point 1 is replaced by the
following:
"‘drug’ means:
(a)          
any of the substances covered by the 1961 United
Nations Single Convention on Narcotic Drugs (as amended by the 1972 Protocol)
and the 1971 United Nations Convention on Psychotropic Substances;
(b)         
any of the substances listed in the Annex;
(c)          
any new psychoactive substance posing severe
health, social and safety risks, subjected to permanent market restriction on
the basis of [Article 13(1) of Regulation (EU) No …/… on new psychoactive
substances];"
(2)                   
In Article 9, the following paragraphs 3 and 4
are added:
"3.      In respect of new psychoactive
substances subjected to permanent market restriction on the basis of [Article
13(1) of Regulation (EU) No …/… on new psychoactive substances], Member
States shall bring into force the laws, regulations and administrative
provisions necessary to apply the provisions of this Framework Decision to
these new psychoactive substances within twelve months after entry into force
of the permanent market restriction. They shall forthwith communicate to the
Commission the text of those provisions.
When Member States adopt those provisions, they
shall contain a reference to this Framework Decision or be accompanied by such
a reference on the occasion of their official publication. Member States shall
determine how such reference is to be made.
4.       By [5 years after entry into force
of this Directive and every 5 years thereafter], the Commission shall
assess the extent to which the Member States have taken the necessary measures
to comply with this Framework Decision and publish a report."
(3)                   
An Annex, as set out in the Annex to this
Directive, is added.
Article 2
Transposition
Member States shall bring into force the
laws, regulations and administrative provisions necessary to comply with this
Directive by [twelve months after entry into force] at the latest. They
shall forthwith communicate to the Commission the text of those provisions.
When Member States adopt those provisions,
they shall contain a reference to this Directive or be accompanied by such a
reference on the occasion of their official publication. Member States shall
determine how such reference is to be made.
Article 3
Entry
into force
This Directive
shall enter into force on [the same day as entry into force of Regulation
(EU) No …/… on new psychoactive substances].
Article 4
Addressees
This
Directive is addressed to the Member States in accordance with the Treaties.
Done at Brussels,
For the European Parliament                       For
the Council
The President                                                 The
President
ANNEX
List of substances referred to in point (1)(b) of Article 1
(a)                   
P-Methylthioamphetamine or
4-Methylthioamphetamine,
as referred to in Council Decision 1999/615/JHA of 13 September 1999 defining
4-MTA as a new synthetic drug which is to be made subject to control measures
and criminal penalties[10].
(b)                   
Paramethoxymethylamphetamine or N-methyl-1-(4-methoxyphenyl)-2-aminopropane,
as referred to in Council Decision 2002/188/JHA of 28 February 2002 concerning
control measures and criminal sanctions in respect of the new synthetic drug
PMMA[11].
(c)                   
2,5-dimethoxy-4-iodophenethylamine, 2,5-dimethoxy-4-ethylthiophenethylamine,
2,5-dimethoxy-4-(n)-propylthiophenethylamine and 2,4,5-trimethoxyamphetamine,
as referred to in Council Decision 2003/847/JHA of 27 November 2003 concerning
control measures and criminal sanctions in respect of the new synthetic drugs
2C-I, 2C-T-2, 2C-T-7 and TMA-2[12].
(d)                   
1-benzylpiperazine or
1-benzyl-1,4-diazacyclohexane or N-benzylpiperazine or benzylpiperazine as
referred to in Council Decision 2008/206/JHA of 3 March 2008 on defining
1-benzylpiperazine (BZP) as a new psychoactive substance which is to be made
subject to control measures and criminal provisions[13]. 
(e)                   
4-methylmethcathinone, as referred to in Council Decision
2010/759/EU of 2 December 2010 on submitting
4-methylmethcathinone (mephedrone) to control measures[14].
(f)                     
4-methylamphetamine, as referred to in Council
Decision 2013/129/EU of 7 March 2013 on subjecting 4-methylamphetamine to control
measures[15].

(g)                   
5-(2-aminopropyl)indole, as referred to in [Council
Decision 2013/…/JHA of … on subjecting 5-(2-aminopropyl) indole to control
measures[16]].
[1]               The 1961 United Nations Single Convention on Narcotic
Drugs (as amended by the 1972 Protocol) and the 1971 United Nations Convention
on Psychotropic Substances.
[2]               European Monitoring Centre for Drugs and Drug
Addiction, The state of the drugs problem in Europe, Annual Report 2012. http://www.emcdda.europa.eu/publications/annual-report/2012
[3]               COM(2011) 689 final.
[4]               OJ L 127, 20.5.2005, p. 32.
[5]               OJ L 335, 11.11.2004, p. 8.
[6]               OJ L 167, 25.6.1997, p. 1.
[7]               OJ L 335, 11.11.2004, p. 8.
[8]               OJ L 167, 25.06.1997, p. 1.
[9]               OJ L 127, 10.05.2005, p. 32.
[10]             OJ L 244, 16.09.1999, p.1.
[11]             OJ L 063, 06.03.2002, p. 14.
[12]             OJ L 321, 6.12.2003, p. 64.
[13]             OJ L 63, 7.03.2008, p. 45.
[14]             OJ L 322, 8.12.2010, p. 44.
[15]             OJ L 72, 15.03.2013, p. 11.
[16]             OJ L […], […], p. […].